Advertisement

The evidence strength of a meta-analysis of aspirin for primary prevention of cancer

  • Qibiao WuEmail author
  • Elaine Laihan Leung
Letter to the Editor

Abstract

Dr. Tarek Haykal et al. (145:1795–1809, 2019) reported a meta-analysis of aspirin for the primary prevention of cancer in individuals without known cancer. The authors found that aspirin use was not associated with significant reduction in cancer mortality or incidence, but with higher rates of bleeding. The findings of this study added some evidence to the clinical practice. However, several issues might have compromised the strength of the evidence of this systematic review. If the investigators could have further clarified the inclusion and exclusion criteria, included all eligible studies, extracted data more meticulously, and performed more necessary sensitivity analyses to confirm the robustness of their findings, the strength of evidence of this meta-analysis would have been stronger.

Keywords

Letter to the editors Evidence Strength Meta-analysis Aspirin Primary prevention Cancer 

Notes

Acknowledgements

This work was funded by The Science and Technology Development Fund, Macau SAR (File No. 130/2017/A3, 0099/2018/A3, 0096/2018/A3).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518–527.  https://doi.org/10.1016/S1470-2045(12)70112-2 CrossRefPubMedGoogle Scholar
  2. Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899.  https://doi.org/10.1056/NEJMoa021735 CrossRefPubMedGoogle Scholar
  3. Barton MK (2012) Daily aspirin reduces colorectal cancer incidence in patients with Lynch syndrome. CA Cancer J Clin 62:143–144.  https://doi.org/10.3322/caac.21136 CrossRefPubMedGoogle Scholar
  4. Burn J et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578.  https://doi.org/10.1056/NEJMoa0801297 CrossRefPubMedGoogle Scholar
  5. Cook NR et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55.  https://doi.org/10.1001/jama.294.1.47 CrossRefPubMedGoogle Scholar
  6. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159:77–85.  https://doi.org/10.7326/0003-4819-159-2-201307160-00002 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Critical Leg Ischaemia Prevention Study G, Catalano M, Born G, Peto R (2007) Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261:276–284.  https://doi.org/10.1111/j.1365-2796.2006.01763.x CrossRefGoogle Scholar
  8. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255–1262CrossRefGoogle Scholar
  9. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634.  https://doi.org/10.1136/bmj.315.7109.629 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Farrell B, Godwin J, Richards S, Warlow C (1991) The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54:1044–1054.  https://doi.org/10.1136/jnnp.54.12.1044 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Fowkes FG et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303:841–848.  https://doi.org/10.1001/jama.2010.221 CrossRefPubMedGoogle Scholar
  12. Gaziano JM et al (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392:1036–1046.  https://doi.org/10.1016/s0140-6736(18)31924-x CrossRefPubMedGoogle Scholar
  13. Guyatt G et al (2013) GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 66:151–157.  https://doi.org/10.1016/j.jclinepi.2012.01.006 CrossRefPubMedGoogle Scholar
  14. Hansson L, HOT Study Group et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351:1755–1762.  https://doi.org/10.1016/s0140-6736(98)04311-6 CrossRefPubMedGoogle Scholar
  15. Haykal T et al (2019) Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 145:1795–1809.  https://doi.org/10.1007/s00432-019-02932-0 CrossRefPubMedGoogle Scholar
  16. Higgins JGS (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. (2011)Google Scholar
  17. Hull MA et al (2018) Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 factorial trial. Lancet 392:2583–2594.  https://doi.org/10.1016/s0140-6736(18)31775-6 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Morimoto T, Nakayama M, Saito Y, Ogawa H (2007) Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb 14:159–166.  https://doi.org/10.5551/jat.e482 CrossRefPubMedGoogle Scholar
  19. Ogawa H et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134–2141.  https://doi.org/10.1001/jama.2008.623 CrossRefPubMedGoogle Scholar
  20. Okada S et al (2018) Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care 41:1757–1764.  https://doi.org/10.2337/dc18-0368 CrossRefPubMedGoogle Scholar
  21. Peto R et al (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 296:313–316.  https://doi.org/10.1136/bmj.296.6618.313 (Clin Res Ed) CrossRefGoogle Scholar
  22. Schoenberger JA (1980) A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661–669CrossRefGoogle Scholar
  23. The Coronary Drug Project Research Group (1980) Aspirin in coronary heart disease. Circulation 62:V59–V62Google Scholar
  24. The DAMAD Study Group (1989) Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 38:491–498CrossRefGoogle Scholar
  25. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ (2015) Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 21:756–762.  https://doi.org/10.1158/1078-0432.CCR-14-2235 CrossRefPubMedGoogle Scholar
  26. Yokoyama K et al (2018) Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Res Pract Thromb Haemost 2:274–281.  https://doi.org/10.1002/rth2.12097 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau Institute for Applied Research in Medicine and HealthMacau University of Science and TechnologyMacauChina

Personalised recommendations